Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 placebo-controlled study of ISIS 766720 added to somatostatin receptor ligands in acromegaly
2017-004259-22Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Apr 2018
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acromegaly comparing ISIS 766720 add-on to long-acting SRL with Placebo add-on to long-acting SRL (2 arms). Primary endpoint: Percent change in serum IGF-1 from baseline to 28 days after last dose. Started Apr 2018; status: completed.
02
Drugs
cimdelirsen
03
Conditions
acromegaly
Beyond the preview
Go deeper on 2017-004259-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004259-22.